1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- AstraZeneca PLC
- GE Healthcare
- GlaxoSmithKline Plc
- Novartis AG
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Biotechnology in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
- The UK biotechnology market had total revenues of $12.1bn in 2020, representing a compound annual growth rate (CAGR) of 8.5% between 2016 and 2020.
- The medical/healthcare segment was the market's most lucrative in 2020, with total revenues of $8.0bn, equivalent to 66% of the market's overall value.
- Despite the challenging market conditions created by the COVID-19 pandemic, growth in the UK market has continued to be supported by strong financing. In fact, UK-based biotech companies raised a total of £2.8bn ($3.6bn) in 2020, making it a record year.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United Kingdom
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United Kingdom
- Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom biotechnology market with five year forecasts
Reasons to Buy
- What was the size of the United Kingdom biotechnology market by value in 2020?
- What will be the size of the United Kingdom biotechnology market in 2025?
- What factors are affecting the strength of competition in the United Kingdom biotechnology market?
- How has the market performed over the last five years?
- What are the main segments that make up the United Kingdom's biotechnology market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca PLC
- GE Healthcare
- GlaxoSmithKline Plc
- Novartis AG
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Category segmentation
1.4. Geography segmentation
1.5. Market rivalry
1.6. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
4 Market Segmentation
4.1. Category segmentation
4.2. Geography segmentation
5 Market Outlook
5.1. Market value forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What strategies do leading players follow?
7.3. What are the strengths of leading players?
7.4. What has been the rationale behind recent M&A activity?
7.5. How might the COVID-19 pandemic affect the competitive landscape?
8 Company Profiles
8.1. AstraZeneca PLC
8.2. Novartis AG
8.3. GlaxoSmithKline Plc
8.4. GE Healthcare
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related Research
10.4. About the Author
List of Tables
Table 1: United Kingdom biotechnology industry value: $ billion, 2016-20
Table 2: United Kingdom biotechnology industry category segmentation: $ billion, 2020
Table 3: United Kingdom biotechnology industry geography segmentation: $ billion, 2020
Table 4: United Kingdom biotechnology industry value forecast: $ billion, 2020-25
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: Annual Financial Ratios
Table 7: AstraZeneca PLC: Key Employees
Table 8: Novartis AG: key facts
Table 9: Novartis AG: Annual Financial Ratios
Table 10: Novartis AG: Key Employees
Table 11: Novartis AG: Key Employees Continued
Table 12: GlaxoSmithKline Plc: key facts
Table 13: GlaxoSmithKline Plc: Annual Financial Ratios
Table 14: GlaxoSmithKline Plc: Annual Financial Ratios (Continued)
Table 15: GlaxoSmithKline Plc: Key Employees
Table 16: GlaxoSmithKline Plc: Key Employees Continued
Table 17: GE Healthcare: key facts
Table 18: GE Healthcare: Key Employees
Table 19: GE Healthcare: Key Employees Continued
Table 20: United Kingdom size of population (million), 2016-20
Table 21: United Kingdom gdp (constant 2005 prices, $ billion), 2016-20
Table 22: United Kingdom gdp (current prices, $ billion), 2016-20
Table 23: United Kingdom inflation, 2016-20
Table 24: United Kingdom consumer price index (absolute), 2016-20
Table 25: United Kingdom exchange rate, 2016-20
List of Figures
Figure 1: United Kingdom biotechnology industry value: $ billion, 2016-20
Figure 2: United Kingdom biotechnology industry category segmentation: % share, by value, 2020
Figure 3: United Kingdom biotechnology industry geography segmentation: % share, by value, 2020
Figure 4: United Kingdom biotechnology industry value forecast: $ billion, 2020-25
Figure 5: Forces driving competition in the biotechnology industry in the United Kingdom, 2020
Figure 6: Drivers of buyer power in the biotechnology industry in the United Kingdom, 2020
Figure 7: Drivers of supplier power in the biotechnology industry in the United Kingdom, 2020
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in the United Kingdom, 2020
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in the United Kingdom, 2020
Figure 10: Drivers of degree of rivalry in the biotechnology industry in the United Kingdom, 2020
1.1. Market value
1.2. Market value forecast
1.3. Category segmentation
1.4. Geography segmentation
1.5. Market rivalry
1.6. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
4 Market Segmentation
4.1. Category segmentation
4.2. Geography segmentation
5 Market Outlook
5.1. Market value forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What strategies do leading players follow?
7.3. What are the strengths of leading players?
7.4. What has been the rationale behind recent M&A activity?
7.5. How might the COVID-19 pandemic affect the competitive landscape?
8 Company Profiles
8.1. AstraZeneca PLC
8.2. Novartis AG
8.3. GlaxoSmithKline Plc
8.4. GE Healthcare
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related Research
10.4. About the Author
List of Tables
Table 1: United Kingdom biotechnology industry value: $ billion, 2016-20
Table 2: United Kingdom biotechnology industry category segmentation: $ billion, 2020
Table 3: United Kingdom biotechnology industry geography segmentation: $ billion, 2020
Table 4: United Kingdom biotechnology industry value forecast: $ billion, 2020-25
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: Annual Financial Ratios
Table 7: AstraZeneca PLC: Key Employees
Table 8: Novartis AG: key facts
Table 9: Novartis AG: Annual Financial Ratios
Table 10: Novartis AG: Key Employees
Table 11: Novartis AG: Key Employees Continued
Table 12: GlaxoSmithKline Plc: key facts
Table 13: GlaxoSmithKline Plc: Annual Financial Ratios
Table 14: GlaxoSmithKline Plc: Annual Financial Ratios (Continued)
Table 15: GlaxoSmithKline Plc: Key Employees
Table 16: GlaxoSmithKline Plc: Key Employees Continued
Table 17: GE Healthcare: key facts
Table 18: GE Healthcare: Key Employees
Table 19: GE Healthcare: Key Employees Continued
Table 20: United Kingdom size of population (million), 2016-20
Table 21: United Kingdom gdp (constant 2005 prices, $ billion), 2016-20
Table 22: United Kingdom gdp (current prices, $ billion), 2016-20
Table 23: United Kingdom inflation, 2016-20
Table 24: United Kingdom consumer price index (absolute), 2016-20
Table 25: United Kingdom exchange rate, 2016-20
List of Figures
Figure 1: United Kingdom biotechnology industry value: $ billion, 2016-20
Figure 2: United Kingdom biotechnology industry category segmentation: % share, by value, 2020
Figure 3: United Kingdom biotechnology industry geography segmentation: % share, by value, 2020
Figure 4: United Kingdom biotechnology industry value forecast: $ billion, 2020-25
Figure 5: Forces driving competition in the biotechnology industry in the United Kingdom, 2020
Figure 6: Drivers of buyer power in the biotechnology industry in the United Kingdom, 2020
Figure 7: Drivers of supplier power in the biotechnology industry in the United Kingdom, 2020
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in the United Kingdom, 2020
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in the United Kingdom, 2020
Figure 10: Drivers of degree of rivalry in the biotechnology industry in the United Kingdom, 2020
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- AstraZeneca PLC
- Novartis AG
- GlaxoSmithKline Plc
- GE Healthcare
Note: Product cover images may vary from those shown
